Generic Name	Camrelizumab
Drug Type	Antibody
Drug Class	Immune therapy
Dose	200 milligrams (mg) per flat dose
Route	i.v.
Schedule of Administration	SHR‐1210 was infused intravenously at a fixed dose of 200 mg once every 2 weeks from the beginning of radiotherapy for up to 32 weeks (i.e., for 16 cycles). Radiotherapy was delivered as RapidArc (volumetric arc) intensity‐modulated RT with a simultaneous integrated boost. The radiotherapy was given according to Chinese treatment guidelines for esophageal carcinoma and was prescribed to cover 95% of the planning gross tumor volume (PGTV), given at 2.0 Gy per fraction, five fractions per week, to a total of 60 Gy over 6 weeks. The dose prescribed to cover 95% of the planning target volume (PTV) was 1.8 Gy per fraction, five fractions per week, for a total of 54 Gy over 6 weeks. Target volumes were as described previously. Briefly, gross tumor volume (GTV) was determined based on the results of upper gastrointestinal radiography, esophageal endoscopy, and chest computed tomography. If lymphatic metastasis was present in the mediastinum, supraclavicular region, or abdominal cavity, GTV in involved lymph nodes was delineated. The clinical target volume (CTV) was delineated as GTV and plus 3‐cm margins in the vertical direction, which covered the corresponding lymphatic drainage areas, and 0.6‐cm margins in the anteroposterior and transverse directions, which did not exceed the anatomic boundary. PGTV and PTV was defined as GTV or CTV plus 5‐mm margins, individually. No additional adjuvant or induction chemotherapy was performed.